Maja Kodani1, Tonya Mixson-Hayden2, Jan Drobeniuc2, Saleem Kamili2. 1. Division of Viral Hepatitis, National Center for HIV, Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30293, United States. Electronic address: mkodani@cdc.gov. 2. Division of Viral Hepatitis, National Center for HIV, Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30293, United States.
Abstract
BACKGROUND: Five viruses have been etiologically associated with viral hepatitis. Nucleic acid testing (NAT) remains the gold standard for diagnosis of viremic stages of infection. NAT methodologies have been developed for all hepatitis viruses; however, a NAT-based assay that can simultaneously detect all five viruses is not available. OBJECTIVES: We designed TaqMan card-based assays for detection of HAV RNA, HBV DNA, HCV RNA, HDV RNA and HEV RNA. STUDY DESIGN: The performances of individual assays were evaluated on TaqMan Array Cards (TAC) for detecting five viral genomes simultaneously. Sensitivity and specificity were determined by testing 329 NAT-tested clinical specimens. RESULTS: All NAT-positive samples for HCV (n = 32), HDV (n = 28) and HEV (n = 14) were also found positive in TAC (sensitivity, 100%). Forty-three of 46 HAV-NAT positive samples were also positive in TAC (sensitivity, 94%), while 36 of 39 HBV-NAT positive samples were positive (sensitivity, 92%). No false-positives were detected for HBV (n = 32), HCV (n = 36), HDV (n = 30), and HEV (n = 31) NAT-negative samples (specificity 100%), while 38 of 41 HAV-NAT negative samples were negative by TAC (specificity 93%). CONCLUSIONS: TAC assay was concordant with corresponding individual NATs for hepatitis A-E viral genomes and can be used for their detection simultaneously. The TAC assay has potential for use in hepatitis surveillance, for screening of donor specimens and in outbreak situations. Wider availability of TAC-ready assays may allow for customized assays, for improving acute jaundice surveillance and for other purposes for which there is need to identify multiple pathogens rapidly. Published by Elsevier B.V.
BACKGROUND: Five viruses have been etiologically associated with viral hepatitis. Nucleic acid testing (NAT) remains the gold standard for diagnosis of viremic stages of infection. NAT methodologies have been developed for all hepatitis viruses; however, a NAT-based assay that can simultaneously detect all five viruses is not available. OBJECTIVES: We designed TaqMan card-based assays for detection of HAV RNA, HBV DNA, HCV RNA, HDV RNA and HEV RNA. STUDY DESIGN: The performances of individual assays were evaluated on TaqMan Array Cards (TAC) for detecting five viral genomes simultaneously. Sensitivity and specificity were determined by testing 329 NAT-tested clinical specimens. RESULTS: All NAT-positive samples for HCV (n = 32), HDV (n = 28) and HEV (n = 14) were also found positive in TAC (sensitivity, 100%). Forty-three of 46 HAV-NAT positive samples were also positive in TAC (sensitivity, 94%), while 36 of 39 HBV-NAT positive samples were positive (sensitivity, 92%). No false-positives were detected for HBV (n = 32), HCV (n = 36), HDV (n = 30), and HEV (n = 31) NAT-negative samples (specificity 100%), while 38 of 41 HAV-NAT negative samples were negative by TAC (specificity 93%). CONCLUSIONS: TAC assay was concordant with corresponding individual NATs for hepatitis A-E viral genomes and can be used for their detection simultaneously. The TAC assay has potential for use in hepatitis surveillance, for screening of donor specimens and in outbreak situations. Wider availability of TAC-ready assays may allow for customized assays, for improving acute jaundice surveillance and for other purposes for which there is need to identify multiple pathogens rapidly. Published by Elsevier B.V.
Authors: Luke A Wiley; Erin R Burnight; Arlene V Drack; Bailey B Banach; Dalyz Ochoa; Cathryn M Cranston; Robert A Madumba; Jade S East; Robert F Mullins; Edwin M Stone; Budd A Tucker Journal: Hum Gene Ther Date: 2016-07-11 Impact factor: 5.695
Authors: Mohammad Irshad; Priyanka Gupta; Dhananjay Singh Mankotia; Mohammad Ahmad Ansari Journal: World J Gastroenterol Date: 2016-05-28 Impact factor: 5.742
Authors: David R McGivern; Hsing-Hua S Lin; Junyao Wang; Tiffany Benzine; Harry L A Janssen; Mandana Khalili; Mauricio Lisker-Melman; Robert J Fontana; Steven H Belle; Michael W Fried Journal: Open Forum Infect Dis Date: 2019-04-09 Impact factor: 3.835
Authors: John J Harvey; Stephanie Chester; Stephen A Burke; Marisela Ansbro; Tricia Aden; Remedios Gose; Rebecca Sciulli; Jing Bai; Lucy DesJardin; Jeffrey L Benfer; Joshua Hall; Sandra Smole; Kimberly Doan; Michael D Popowich; Kirsten St George; Tammy Quinlan; Tanya A Halse; Zhen Li; Ailyn C Pérez-Osorio; William A Glover; Denny Russell; Erik Reisdorf; Thomas Whyte; Brett Whitaker; Cynthia Hatcher; Velusamy Srinivasan; Kathleen Tatti; Maria Lucia Tondella; Xin Wang; Jonas M Winchell; Leonard W Mayer; Daniel Jernigan; Alison C Mawle Journal: J Virol Methods Date: 2015-11-27 Impact factor: 2.014